<DOC>
	<DOCNO>NCT02042066</DOCNO>
	<brief_summary>Low intensity shockwaves proven animal human study increase tissue perfusion , promote angiogenesis tissue regeneration improve neural function . The hypothesis study shockwave therapy could improve symptom patient resistant hypertension .</brief_summary>
	<brief_title>Safety Efficacy Study Extracorporeal Shockwave Therapy Treatment Patients With Resistant Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Coronary Vasospasm</mesh_term>
	<criteria>Subjects provide write informed consent . Age ≥18 ≤80 year old . Office systolic blood pressure remain ≥160 mmHg ( ≥150 mmHg patient type 2 diabetes ) despite stable use ≥3 antihypertensive medication concurrently maximally tolerated dos , one diuretic ( unless tolerance contraindication diuretic ) . Able willing comply require followup schedule . Subjects participate clinical study involve another investigational drug device within 4 week prior Screening . Have hypertension secondary identifiable treatable cause take medication raise BP . Prior renal artery intervention ( balloon angioplasty stenting ) . Pregnancy . Uncompensated heart failure . Chronic Liver Disease . Patients skin wound / infection treatment area . Subjects take oral anticoagulant . Local tumor treatment area .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Resistant Hypertension</keyword>
	<keyword>RH</keyword>
	<keyword>RHT</keyword>
	<keyword>Blood Pressure</keyword>
	<keyword>Kidney</keyword>
	<keyword>Shockwave</keyword>
</DOC>